Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.

Lysine demethylase 5A (KDM5A) is a negative regulator of histone H3K4 trimethylation, a histone mark associated with activate gene transcription. We identify that KDM5A interacts with the P-TEFb complex and cooperates with MYC to control MYC targeted genes in multiple myeloma (MM) cells. We develop a cell-permeable and selective KDM5 inhibitor, JQKD82, that increases histone H3K4me3 but paradoxically inhibits downstream MYC-driven transcriptional output in vitro and in vivo. Using genetic ablation together with our inhibitor, we establish that KDM5A supports MYC target gene transcription independent of MYC itself, by supporting TFIIH (CDK7)- and P-TEFb (CDK9)-mediated phosphorylation of RNAPII. These data identify KDM5A as a unique vulnerability in MM functioning through regulation of MYC-target gene transcription, and establish JQKD82 as a tool compound to block KDM5A function as a potential therapeutic strategy for MM.

[1]  J. Qi,et al.  Using Chemical Epigenetics to Target Cancer. , 2020, Molecular cell.

[2]  Caleb K. Stein,et al.  Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. , 2020, Blood cancer discovery.

[3]  Joshua A. Bittker,et al.  Discovering the anticancer potential of non-oncology drugs by systematic viability profiling , 2020, Nature Cancer.

[4]  Zachary T Herbert,et al.  The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis , 2019, Genes & development.

[5]  Jun Sese,et al.  ChIP‐Atlas: a data‐mining suite powered by full integration of public ChIP‐seq data , 2018, EMBO reports.

[6]  J. Shay,et al.  The aryl hydrocarbon receptor regulates nucleolar activity and protein synthesis in MYC-expressing cells , 2018, Genes & development.

[7]  T. Hideshima,et al.  The biological significance of histone modifiers in multiple myeloma: clinical applications , 2018, Blood Cancer Journal.

[8]  R. Young,et al.  Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry , 2018, Nature Genetics.

[9]  Donald R. Polaski,et al.  Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma , 2018, Nature Genetics.

[10]  B. Quesnel,et al.  Targeting MYC in multiple myeloma , 2017, Leukemia.

[11]  M. Herlyn,et al.  JARID1 Histone Demethylases: Emerging Targets in Cancer. , 2017, Trends in cancer.

[12]  G. Legube,et al.  Histone demethylase KDM5A regulates the ZMYND8–NuRD chromatin remodeler to promote DNA repair , 2017, The Journal of cell biology.

[13]  Y. Tai,et al.  HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications , 2017, Leukemia.

[14]  Akane Kawamura,et al.  Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells , 2017, Cell chemical biology.

[15]  R. Young,et al.  Transcriptional Addiction in Cancer , 2017, Cell.

[16]  S. Mandrup,et al.  The KDM5 family is required for activation of pro-proliferative cell cycle genes during adipocyte differentiation , 2016, Nucleic acids research.

[17]  Bing Ren,et al.  Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition , 2016, Nature.

[18]  R. Prinjha,et al.  Structural analysis of human KDM5B guides histone demethylase inhibitor development. , 2016, Nature chemical biology.

[19]  P. Trojer,et al.  An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. , 2016, Nature chemical biology.

[20]  P. V. van Diest,et al.  Recruitment of the Mammalian Histone-modifying EMSY Complex to Target Genes Is Regulated by ZNF131* , 2016, The Journal of Biological Chemistry.

[21]  J. Secombe,et al.  The Histone Demethylase KDM5 Activates Gene Expression by Recognizing Chromatin Context through Its PHD Reader Motif. , 2015, Cell reports.

[22]  C. Dang,et al.  MYC, Metabolism, and Cancer. , 2015, Cancer discovery.

[23]  S. Jimeno-González,et al.  A positioned +1 nucleosome enhances promoter-proximal pausing , 2015, Nucleic acids research.

[24]  David A. Orlando,et al.  Quantitative ChIP-Seq normalization reveals global modulation of the epigenome. , 2014, Cell reports.

[25]  J. Nakayama,et al.  Physical and Functional Interactions between the Histone H3K4 Demethylase KDM5A and the Nucleosome Remodeling and Deacetylase (NuRD) Complex* , 2014, The Journal of Biological Chemistry.

[26]  Sridhar Ramaswamy,et al.  Targeting transcription regulation in cancer with a covalent CDK7 inhibitor , 2014, Nature.

[27]  Zongzhi Liu,et al.  Histone demethylase RBP2 is critical for breast cancer progression and metastasis. , 2014, Cell reports.

[28]  William B. Smith,et al.  Genome-wide localization of small molecules , 2013, Nature Biotechnology.

[29]  K. Zhao,et al.  Extended Self-Renewal and Accelerated Reprogramming in the Absence of Kdm5b , 2013, Molecular and Cellular Biology.

[30]  Hsien-Da Huang,et al.  Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. , 2013, Cancer research.

[31]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[32]  Stephen H. Hughes,et al.  H3K4me3 Interactions with TAF3 Regulate Preinitiation Complex Assembly and Selective Gene Activation , 2013, Cell.

[33]  William F. Richter,et al.  Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation , 2012, Proceedings of the National Academy of Sciences.

[34]  David A. Orlando,et al.  Revisiting Global Gene Expression Analysis , 2012, Cell.

[35]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[36]  D. Green,et al.  c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells , 2012, Cell.

[37]  A. Waage,et al.  Addiction to c-MYC in multiple myeloma. , 2012, Blood.

[38]  H. Auer,et al.  dKDM5/LID regulates H3K4me3 dynamics at the transcription-start site (TSS) of actively transcribed developmental genes , 2012, Nucleic acids research.

[39]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[40]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[41]  H. Hurst,et al.  Histone Demethylase KDM5B Collaborates with TFAP2C and Myc To Repress the Cell Cycle Inhibitor p21cip (CDKN1A) , 2012, Molecular and Cellular Biology.

[42]  Satchidananda Panda,et al.  Histone Lysine Demethylase JARID1a Activates CLOCK-BMAL1 and Influences the Circadian Clock , 2011, Science.

[43]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[44]  D. Chan,et al.  Analysis of the Human Endogenous Coregulator Complexome , 2011, Cell.

[45]  G. Mulligan,et al.  Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma , 2011, Leukemia.

[46]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[47]  Dinshaw J. Patel,et al.  Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger , 2009, Nature.

[48]  H. Erdjument-Bromage,et al.  The H3K4 Demethylase Lid Associates with and Inhibits Histone Deacetylase Rpd3 , 2008, Molecular and Cellular Biology.

[49]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[50]  D. Singer,et al.  TFIID component TAF7 functionally interacts with both TFIIH and P-TEFb , 2008, Proceedings of the National Academy of Sciences.

[51]  Ming-Daw Tsai,et al.  The ARID domain of the H3K4 demethylase RBP2 binds to a DNA CCGCCC motif , 2008, Nature Structural &Molecular Biology.

[52]  P. L. Bergsagel,et al.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. , 2008, Cancer cell.

[53]  Matthias Mann,et al.  Selective Anchoring of TFIID to Nucleosomes by Trimethylation of Histone H3 Lysine 4 , 2007, Cell.

[54]  K. Helin,et al.  RBP2 Belongs to a Family of Demethylases, Specific for Tri-and Dimethylated Lysine 4 on Histone 3 , 2007, Cell.

[55]  Paul Tempst,et al.  PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. , 2007, Molecular cell.

[56]  D. Gary Gilliland,et al.  The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase , 2007, Cell.

[57]  Zhiping Weng,et al.  Global mapping of c-Myc binding sites and target gene networks in human B cells , 2006, Proceedings of the National Academy of Sciences.

[58]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[59]  Yi Zhang,et al.  JmjC-domain-containing proteins and histone demethylation , 2006, Nature Reviews Genetics.

[60]  Giacomo Finocchiaro,et al.  Myc-binding-site recognition in the human genome is determined by chromatin context , 2006, Nature Cell Biology.

[61]  R. Young,et al.  Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. , 2005, Molecular cell.

[62]  Mark J. Murphy,et al.  c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. , 2004, Genes & development.

[63]  Steven Hahn,et al.  Structure and mechanism of the RNA polymerase II transcription machinery , 2004, Nature Structural &Molecular Biology.

[64]  W. Hong,et al.  Retinoblastoma-binding Protein 2 (Rbp2) Potentiates Nuclear Hormone Receptor-mediated Transcription* , 2001, The Journal of Biological Chemistry.

[65]  Jacob D. Jaffe,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[66]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.